Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

[Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].

Matsko MV.

Vopr Onkol. 2012;58(3):425-8. Russian. No abstract available.

PMID:
22888663
2.

New approaches for temozolomide therapy: use in newly diagnosed glioma.

Stupp R, Newlands E.

Semin Oncol. 2001 Aug;28(4 Suppl 13):19-23. Review.

PMID:
11550135
3.

Temozolomide: a novel oral alkylating agent.

Danson SJ, Middleton MR.

Expert Rev Anticancer Ther. 2001 Jun;1(1):13-9. Review.

PMID:
12113120
4.

Future directions for temozolomide therapy.

Yung WK.

Semin Oncol. 2001 Aug;28(4 Suppl 13):43-6. Review.

PMID:
11550138
5.

Is protracted low-dose temozolomide feasible in glioma patients?

Tosoni A, Cavallo G, Ermani M, Scopece L, Franceschi E, Ghimenton C, Gardiman M, Pasetto L, Blatt V, Brandes AA.

Neurology. 2006 Feb 14;66(3):427-9.

PMID:
16476947
6.

Temozolomide in combination with other cytotoxic agents.

Prados M.

Semin Oncol. 2001 Aug;28(4 Suppl 13):24-33. Review.

PMID:
11550136
7.

[Central nervous system glioma. Multi-drug chemotherapy including temozolomide].

Wakabayashi T.

Gan To Kagaku Ryoho. 2009 Jun;36(6):938-40. Japanese. No abstract available.

PMID:
19579330
8.

Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.

Patel VJ, Elion GB, Houghton PJ, Keir S, Pegg AE, Johnson SP, Dolan ME, Bigner DD, Friedman HS.

Clin Cancer Res. 2000 Oct;6(10):4154-7.

9.

Temozolomide in patients with high grade gliomas.

Brandes AA, Pasetto LM, Vastola F, Monfardini S.

Oncology. 2000 Sep;59(3):181-6. Review.

PMID:
11053983
10.

Benefits of adjuvant chemotherapy in high-grade gliomas.

DeAngelis LM.

Semin Oncol. 2003 Dec;30(6 Suppl 19):15-8. Review.

PMID:
14765379
11.

Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide.

Neyns B, Cordera S, Joosens E, Pouratian N.

J Clin Oncol. 2008 Sep 20;26(27):4518-9. doi: 10.1200/JCO.2008.18.8177. No abstract available. Erratum in: J Clin Oncol. 2009 Jun 20;27(18):3070. Nader, Pouratian [corrected to Pouratian, Nader].

PMID:
18802168
12.

Optimal role of temozolomide in the treatment of malignant gliomas.

Stupp R, van den Bent MJ, Hegi ME.

Curr Neurol Neurosci Rep. 2005 May;5(3):198-206. Review.

PMID:
15865885
13.

Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.

Levin VA.

Oncology (Williston Park). 2015 Apr;29(4):264, 266-8. No abstract available.

14.

Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.

Motomura K, Natsume A, Wakabayashi T.

J Neurooncol. 2012 Jan;106(1):209-11. doi: 10.1007/s11060-011-0651-0. Epub 2011 Jul 3. No abstract available.

PMID:
21725854
15.

Is protracted low-dose temozolomide feasible in glioma patients?

Wong ET.

Neurology. 2006 Aug 8;67(3):543-4; author reply 543-4. No abstract available. Erratum in: Neurology. 2006 Oct 10;67(7):1315.

PMID:
16894133
16.

Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.

Rinne ML, Wen PY.

Oncology (Williston Park). 2015 Apr;29(4):265, 275. No abstract available.

17.

Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.

Pitini V, Arrigo C, Righi M.

Cancer. 2004 Dec 15;101(12):2900-1; author reply 2901-2. No abstract available.

18.

Carboplatin and oral cyclophosphamide combination after temozolomide failure in malignant gliomas.

Yaman E, Buyukberber S, Uner A, Coskun U, Yamac D, Ozturk B, Kaya AO, Yildiz R, Benekli M; Anatolian Society of Medical Oncology (ASMO)..

Tumori. 2008 Sep-Oct;94(5):674-80.

19.

The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.

Friedman HS, Keir ST, Houghton PJ.

Cancer. 2003 May 1;97(9 Suppl):2359-62. Review.

20.

Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.

Gruber ML, Buster WP.

Am J Clin Oncol. 2004 Feb;27(1):33-8.

PMID:
14758131

Supplemental Content

Support Center